The rising popularity of cannabidiol (CBD) has ignited conversations about its potential benefits, but SAMHSA’s advisory fact sheet sheds light on crucial considerations. Non-FDA-approved CBD products have garnered significant attention due to their marketing for various health conditions and polls indicate a substantial increase in CBD product usage among Americans. The fact sheet raises concerns about the safety of CBD products, highlighting the differences between commercial CBD products and those used in clinical studies. The absence of federal standards for content, purity, and potency, combined with the lack of quality control, can lead to unintended intoxication, particularly among children. The fact sheet serves as an important resource for CBD consumers, clarifying common misconceptions about CBD, outlining the potential risks associated with CBD use, and warning of the pressing need for clarity in the CBD landscape. View the SAMHSA Advisory Factsheet on CBD.
Last Updated on August 23, 2023 by Aimed Alliance
